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Barrett’s esophagus is the substitution of squamous epithelium of the distal esophagus by columnar epithelium.
Intestinal metaplasia in Barrett’s esophagus is considered to be the main risk factor for the development of adenocarcinoma.
Diffuse adenocarcinoma and Barrett’s esophagus without intestinal metaplasia are rare, and reports on the subject are scarce.
PURPOSE AND METHOD: To estimate the prevalence of adenocarcinoma in 297 patients with Barrett’s esophagus,
during the period of 1990 to 2002, and in 13 patients undergoing surgery, to conduct detailed macroscopic and microscopic
analysis, with performance of immunohistochemical tests for p53 and Ki67, correlating the type of tumor with its adjacent
epithelium.
RESULTS: In our patients with Barrett’s esophagus, there was a prevalence of 5.7% of adenocarcinoma. The tumors
developed only when the Barrett’s esophagus segment was long (>3.0 cm). Tumors were located close to the squamous-
columnar junction. The histological study revealed 2 patients (15.4%) with Barrett’s esophagus adjacent to a tumor with
gastric metaplasia without the presence of intestinal metaplasia. Tumors were classified according to Nakamura’s classification
(23% differentiated pattern, and 77% undifferentiated pattern) and to Lauren´s classification (61% intestinal and 39%
diffuse). The difference is due to the migration of microtubular and foveolar tumors of undifferentiated (gastric) pattern in
Nakamuras classification to the Lauren’s intestinal type. The immunohistochemical test for Ki67 was strongly positive in all
the patients, thus evidencing intense cell proliferation in both the columnar epithelium and tumor. Expression of p53 was
negative in 67% of the adjacent columnar epithelia and 42% of the tumors, without any correlation between the tissue types.
CONCLUSION: Adenocarcinoma develops from mixed columnar epithelium, either intestinal or gastric, showing
both the gastric and the intestinal patterns; thus, tumors can also grow in columnar epithelium without intestinal metaplasia.
Barrett’s esophagus should be followed up for the possibility of progression to malignancy, especially when the segment is
longer than 3 cm.
KEYWORDS: Barrett’s Esophagus. Gastroesophageal Reflux. Esophageal Neoplasia. Adenocarcinoma.
Immunohistochemistry.
Currently, Barrett’s esophagus is defined as the presence
of columnar epithelium in the esophagus with intestinal
metaplasia2-6 Other investigators consider Barrett´s
esophagus to be just the substitution of the stratified epi-
thelium in the distal esophagus by columnar epithelium,
either gastric (junctional) or intestinal.1,7-9 The columnar
epithelium with intestinal metaplasia is more frequently
seen than the gastric type.10 Macroscopically, Barrett´s
esophagus is classified as long when it presents a segment
of columnar epithelium longer than 3 cm, and short when
it is shorter than 3 cm.10,11,12
In some specimens of esophagectomy for adenocarci-
noma in Barrett´s esophagus (ABE), the adjacent columnar
epithelium frequently presents with intestinal metaplasia
with a dysplastic alteration.2 However, others present with
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a gastric epithelium type adjacent to the tumor.13-15 Despite
those findings, by the end of 1980s, intestinal metaplasia
was specifically defined as a predictive factor for develop-
ment of ABE,2,6,17-23 and the presence of gastric columnar
epithelium in the distal esophagus was not associated with
adenocarcinoma development.24,25 However, some reports
mention adenocarcinomas growing in Barrett´s esophagus
without intestinal metaplasia in columnar epithelium.16,26,27
Another risk factor for adenocarcinoma development is
the extent of the columnar epithelium in the esophagus,6,18,28
being more frequent in Barrett´s esophagus with segments
longer than 4 cm.7,25,26,29
The most used classification of ABE is the Lauren´s clas-
sification of gastric tumors,30 which divides neoplasia into
diffuse and intestinal according to the microscopic mor-
phology shown by the tumors. There are other detailed clas-
sifications, such as Nakamura´s,31 which classifies gastric
adenocarcinomas into differentiated and undifferentiated
types. The first originates from gastric intestinal metapla-
sia and the latter from the gastric mucosa itself.
The progression of columnar epithelium to dysplastic
and to adenocarcinoma has been studied in the last decade
with genetic and immunohistochemical (IHC) markers,33-35
aiming to identify some marker that could predict evolu-
tion of Barrett´s esophagus to adenocarcinoma.28 Studies of
p53 in Barrett´s esophagus show high positive expression
rates of IHC markers in patients with high degrees of dys-
plasia and adenocarcinoma, and rare expression in normal
mucosae or in esophagitis.36,37,38 Cell proliferation has been
reported to be one of the first steps in the development of
ABE, and it can be induced by chronic cell damage caused
by gastroesophageal reflux. The IHC-identified expression
of Ki67 in Barrett´s esophagus has been studied to evalu-
ate the increased cell proliferation,40 which was found to
be enhanced only in ABE and in high-degree dysplasia, less
expressed in low-degree dysplasia and Barrett´s esophagus
without dysplasia.41 Since this is a simple exam that can be
performed in most large centers, the study of the associa-
tion of Ki67 and p53 has been employed with the purpose
of trying to define intermediate biological markers in ABE
development through dysplasia, as well as to differentiate
dysplasia from adenocarcinoma. The expression of Ki67 and
p53 together has already been studied.41-34 The presence of
those markers in Barrett´s esophagus, both in the dysplas-
tic epithelium and in ABE, has not yet been standardized,
and there is great variation in the results. The study of IHC
reactions to correlate adenocarcinoma with adjacent colum-
nar epithelium has not yet been accomplished.
The objective of this study was to estimate the preva-
lence of adenocarcinoma in patients with Barrett´s
esophagus, to evaluate the extension of the columnar epi-
thelium and the extension and location of the adenocarci-
nomas; to identify the different histological types of tumor
growth in Barrett´s esophagus and to correlate them to the
histological type of the adjacent columnar epithelium, and
to analyze, using IHC tests, expression of p53 and Ki67 in
both the tumor and the adjacent columnar epithelium.
MATERIALS AND METHODS
From January 1990 to June 2002, the medical records
of a total of 297 patients with Barrett´s esophagus, hospi-
talized at the Department of Gastroenterology of the Fac-
ulty of Medicine, University of São Paulo, were retrospec-
tively analyzed. Adenocarcinoma was evidenced in 17 pa-
tients, with a prevalence of 5.7% of ABE.
Gastric fundus and cardia tumors invading the
esophagus were excluded. From the 17 patients, 3 presented
with advanced neoplasia and underwent palliative treatment
without tumor resection. One patient underwent argon plas-
matic ablation of the columnar epithelium, including the
tumor, which was not identified in the histopathological
study of the resected esophagus. The remaining 13 patients
underwent esophageal resection and were the main focus
of this study. This sample comprised 11 men (84.6%) and
2 women (15.4%), a 5.5:1 ratio. Twelve (92.3%) were white,
with ages ranging from 40 to 75 years (mean 60.75 ± SD =
9.88).
Histopathological study
The resected esophagus was opened longitudinally,
photographed, stretched onto a plain plastic or cardboard
surface, and kept in a 10% formol solution for 1 to 4 days.
After this period, the tissue was photographed again and
the columnar epithelium and tumor lengths were measured.
The distances from the distal limit of the tumor to the
gastroesophageal junction (Dist. Tu-GEJ) and from the
proximal limit of the tumor to the columnar-squamous tran-
sition (Dist. Tu-Tepit) were assessed.
Paraffin blocks containing fragments of tumor and ad-
jacent epithelia were sectioned, stained with hematoxylin-
eosin (H&E), and prepared for histological analysis by light
microscopy.
The histological type of the columnar epithelium adja-
cent to the tumor was classified into (i) fundic, consisting
of parietal and main cells; (ii) gastric (pyloric or cardiac),
consisting of mucous glands without parietal cells; (iii) in-
testinal, with a villiform surface with crypts and goblet cells
(specialized columnar epithelium); and (iv) mixed, which
could be associated with more than one type of epithelium.
Tumors were classified according to Laurén30 and
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Nakamura´s31 classification, as modified by Iryia et al.
(1999) for gastric adenocarcinomas, generally used by the
Brazilian Pathology Association (BPA)32 (Table 1).
Immunohistochemical study
The expression of p53 and Ki67 antigens was revealed
by immunohistochemical (IHC) tests of adenocarcinomas
and adjacent columnar epithelia. Biological material from
the columnar epithelium and adjacent adenocarcinoma of
9 and 12 patients, respectively, was recovered in paraffin
for the IHC tests that were performed using Banks´ tech-
nique42. After this reaction, the catalyzed antibody gener-
ated a brown color expressed in the cellular nuclei when
the antigen that was the subject of analysis was present. The
expression of the IHC reaction was analyzed in the most
red-stained areas, when present, and quantitatively classi-
fied as negative (-) (no nuclei expression); minimal (+) (nu-
clei expression up to 5 cells per gland, or discretely (< 33%
of nuclei expression of the total area) in undifferentiated
neoplasias); moderate (++) (nuclei expression from 5 to 10
cells per gland, or (between 33% and 66% of nuclei ex-
pression of total area) in undifferentiated neoplasias); and
maximal (+++) (nuclei expression above 10 cells per gland,
or intensely (> 66% of nuclei expression of total area) in
undifferentiated neoplasias).
Histopathological Results
Measurements obtained from each resected esophagus
are shown in Table 2. Columnar epithelium length ranged
from 3.5 to 16.0 cm (mean 7.71 cm, SD = 3.33). Tumor
length ranged from 1.5 to 7.4 cm (mean 4.67 cm, SD = 2.28).
All the adenocarcinomas developed in cases of Barrett´s
esophagus segments longer than 3.0 cm, and were more fre-
quent in the longest ones (>6.0 cm). Distances from the
distal limit of the tumor to the gastroesophageal junction
(Dist. Tu-GEJ) ranged from tumors located in the GEJ (5
patients – 38.5%) to tumors located 14 cm away from the
GEJ (mean 2.07 cm) (Figure 1). Distances from the proxi-
Table 1 – Comparison between Laurén’s and the Brazilian Pathology Association’s (BPA) classifications for gastric
adenocarcinoma.
BPAIntestinal Pattern LAURÉN(Type) BPAGastric Pattern LAURÉN(Type)
Tubulo-papilliferous Intestinal Tubulopapilliferous(foveolar)* Intestinal
Tubular well differentiated Intestinal Microtubular* Intestinal
Tubular mild differentiated Intestinal Mucinous mucocellular – Poorly differentiated Diffuse
Mucinous muconodular – Poorly differentiated Diffuse
* Some pathologists classify these tumors as Laurén’s intestinal type.
Table 2 – Lengths of columnar epithelium and adenocarcinoma. Distances from adenocarcinoma to gastroesophageal
junction: distances from the adenocarcinoma to the squamous-columnar transition after esophageal resection for treatment
of adenocarcinoma in Barrett’s esophagus.
Patient Barrett´s esophagus length (cm) Tumor length (cm) Dist. Tu-GEJ (cm) Dist. Tu-Tepit. (cm)
1 16 3.6 14 0.4
2 10 8 0.5 1.5
3 4 3.0 1 0
4 7 6.5 0 0.5
5 8 5 0 3
6 6 7.4 2.2 0
7 3.5 3 0 0.5
8 5 4.5 0.3 0.5
9 10.7 2.2 5.5 2.5
10 8 7 0 1
11 6.5 1.5 1.5 3.5
12 9.5 7 2.5 0
13 6 2.5 0 3.5
Mean (SD) 7.71 (3.33) 4.67 (2.28) 2.07 1.30
Min 3.5 1.5 0 0
Max 16 7.4 14 3.5
Dist. Tu-GEJ = Distance from distal limit of the tumor to the gastroesophageal junction. Dist. Tu-Tepit = Distance from the proximal limit of
the tumor to the epithelium (columnar-squamous) transition.
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mal limit of the tumors and the columnar-squamous transi-
tion (Dist. Tu-Tepit) ranged from tumors reaching the epi-
thelium transition (Tepit) to some 3.5 cm away from Tepit
(mean 1.30 cm). Eight tumors (61.5%) were located less
than 1.0 cm from Tepit.
Histopathological classifications of adenocarcinomas
and their adjacent columnar epithelia are presented in Ta-
ble 3. Two patients (15.4%) did not have intestinal meta-
plasia in epithelium adjacent to the adenocarcinoma but
rather had gastric columnar epithelium (Figure 2). Two pa-
tients (15.4%) had only intestinal metaplasia epithelium
beside the tumor; and 9 (69.2%) had both intestinal meta-
plasia and gastric epithelium adjacent to the adenocarci-
noma (one predominately intestinal and 8 predominantly
the gastric type).
According to the Laurén´s classification, 8 patients
(61%) presented with intestinal and 5 (39%) with diffuse
type tumors. Following the BPA classification, 10 patients
presented with adenocarcinoma of the gastric pattern (77%)
and 3 (23%) of the intestinal pattern. Three (23%) of the
gastric pattern tumors were tubulo-papilliferous (foveolar
structure) (Figure 3), 2 (15%) were microtubular, and 5 (39%)
were poorly differentiated. One of the intestinal pattern was
well differentiated (8%), and 2 were mildly differentiated
(15%). The gastric pattern tumors classified as microtubu-
lar and tubulo-papilliferous with foveolar structure, follow-
ing the BPA classification, were defined as intestinal pat-
tern when analyzed by Laurén´s classification (Figure 4).
Table 3 - Histological study: adjacent columnar epithelium and adenocarcinoma in Barrett’s esophagus - Brazilian Pathology
Association’s (BPA) and Laurén’s classifications.
Columnar epithelium Adenocarcinoma
Patients Type BPA LAURÉN
1 Mixed Tubular, well differentiated Intestinal Intestinal
2 Intestinal Tubular, mildly differentiated Intestinal Intestinal
3 Mixed Tubulo-papilliferous. (foveolar structure) Gastric Intestinal
4 Intestinal Tubular, mildly differentiated Intestinal Intestinal
5 Mixed Poorly differentiated Gastric Diffuse
6 Gastric Tubular (foveolar structure) Gastric Intestinal
7 Gastric Microtubular Gastric Intestinal
8 Mixed Poorly differentiated Gastric Diffuse
9 Mixed Poorly differentiated Gastric Diffuse
10 Mixed Microtubular Gastric Intestinal
11 Mixed Tubulo-papilliferous. (foveolar structure) Gastric Intestinal
12 Mixed Poorly differentiated Gastric Diffuse
1 3 Mixed Poorly differentiated Gastric Diffuse
Mixed = columnar epithelium with intestinal metaplasia and gastric metaplasia.
Figure 2 - Columnar epithelium in distal esophagus without intestinal
metaplasia (Barrett’s esophagus of gastric type).
Figure 1 - Undifferentiated adenocarcinoma in Barrett’s esophagus
with 10.7 cm, 5.5 cm distant from gastroesophageal junction.
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However, when the adjacent epithelium of these patients
was studied, no intestinal metaplasia epithelium was seen
in 2 of them.
Immunohistochemical results
The results of the immunohistochemical (IHC) analysis
are listed in Table 4. The tests for Ki67 were moderately or
strongly positive in all 13 patients for both the columnar
epithelia and the adenocarcinomas.
Regarding the IHC reaction for p53 in the columnar epi-
thelium adjacent to the tumor, we tested tissue from 9 pa-
tients. The IHC reaction to p53 was absent in 6 patients
(66.7%), minimal in 1 (11.1%), mild in 1 (11.1%), and maxi-
mal in another 1 (11.1%). Regarding the IHC reaction for
p53 in the adenocarcinoma, we tested tissue from 12 pa-
tients. Reactions to p53 were absent in 5 patients (41.7%),
minimal in 1 (8.3%), and maximal in 6 (50%). Three pa-
tients expressed p53 in the tumor but not in the adjacent
columnar epithelium. Three patients expressed p53 in both
tumor and columnar epithelium.
There was no clear relationship between the IHC reac-
tion for p53 in columnar epithelia and adjacent adenocar-
cinomas for any combination of tissue types (Tables 3 and
4). In 3 patients with mixed columnar epithelium having
gastric or intestinal metaplasia, reaction to p53 in the epi-
Figure 4 - Difference between Laurén’s and Brazilian Pathology
Association’s (BPA) classifications, with migration of tumors from the
gastric (BPA) to the intestinal (Laurén) classification. Tub = tubular;
diff= differentiated; tubulopap= tubulo-papilliferous.
Figure 3 - Tubular adenocarcinoma with foveolar structure (originated
in gastric cells).
Table 4 - Immunohistochemical (IHC) study results: analysis of Ki67 and p53 expression in columnar epithelium and
adenocarcinoma.
Patients Ki67BE Ki67Adenocarcinoma p53BE p53Adenocarcinoma
1 + +++ - +++
2 * ++ * -
3 * +++ * -
4 * * * *
5 ++ ++ ++ +++
6 * ++ * +++
7 + +++ + +++
8 ++ +++ - +
9 +++ ++ - -
10 ++ +++ - -
11 ++ +++ - -
12 +++ +++ +++ +++
13 +++ +++ - +++
* Paraffin material not available. (-) No IHC reaction; (+) Minimal IHC reaction; (++) Moderate IHC reaction; (+++) Maximal IHC reaction;
BE = Barrett’s esophagus
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thelium was negative but was positive in the adjacent tumor.
Conversely, 2 patients that had positive p53 tests in their
tumors also had positive p53 tests in the adjacent colum-
nar epithelium. In the 2 patients with gastric type colum-
nar epithelium, tests for p53 in their tumors were positive,
but in the columnar epithelium, 1 tested positive and 1
negative for p53. Four patients having diffuse or intestinal
type tumors and mixed columnar epithelium had negative
tests for p53 for both tumor and epithelial tissue.
One patient who presented with mixed columnar epi-
thelium with gastric and intestinal metaplasia had p53 ex-
pressed just in gastric cells and never in goblet cells. In this
patient, the tumor was classified as a gastric pattern by BPA
(poorly differentiated) and diffuse by Laurén’s classifica-
tion, with p53 expression in some areas of the tumor lamina.
This kind of expression suggests that the adenocarcinoma
developed from gastric type epithelium, without intestinal
metaplasia.
DISCUSSION
Prevalence of ABE has been decreasing in the last 2 dec-
ades in our service, as well as in other services.44,45 In our
hospital, the prevalence decreased from 16% in 198745 to
5.7% in this study. This reduction might be explained by
the higher number of endoscopic examinations presently
performed in patients with fewer symptoms, thus increas-
ing the diagnosis of Barrett´s esophagus without adenocar-
cinoma46 and decreasing the prevalence rate.
Short Barrett´s esophagus segments can be a risk factor
for development of adenocarcinoma, but this is not well
documented because many previous studies excluded pa-
tients with short Barrett´s esophagus segments from follow-
up.15,20 Some authors describe a lower prevalence of adeno-
carcinoma associated with short Barrett´s esophagus seg-
ments, since the risk area for developing a malignancy (co-
lumnar epithelium) is smaller.3 In this study, however, an
adenocarcinoma developed only in cases of long Barrett´s
esophagus segments (mean 7.71 cm). This finding had pre-
viously been observed in our service, with a mean Barrett´s
esophagus segment length of 9.7 cm for patients develop-
ing adenocarcinoma.29
The location of ABE seems to correlate with the length
of the columnar epithelium. Nearly one third of patients had
the tumor distally next to the GEJ, and another one ex-
tended past it. In other patients, the tumor was up to 14 cm
away from the GEJ, which correlates with lengthier colum-
nar epithelia. Tumors tended to be located next to the sq-
uamous-columnar transition, and the mean distance to the
latter was 1.3 cm. The same was observed in 13 patients
with precocious adenocarcinoma. These findings suggest
that this area should be specifically targeted during ABE
follow up, with endoscopic biopsies.26
Nakamura et al. performed detailed study of gastric mu-
cosa microcarcinomas and described the histogenesis of ad-
enocarcinoma.31 They examined stomach resections per-
formed because of benign diseases and identified tumors
less than 2 mm and between 2 and 5 mm in length. The
results confirmed that mucocellular adenocarcinoma devel-
oped from the gastric mucosa itself, and tubular adenocar-
cinoma from atrophic mucosa with intestinal metaplasia.
Next, when they studied tumors greater than 6 mm, they
found the same relationship of the tumor with the adjacent
columnar epithelium. With statistical analysis they proved
that gastric or undifferentiated adenocarcinomas were re-
lated to gastric mucosa (with pyloric or fundic glands),
while the intestinal pattern or differentiated adenocarcino-
mas were related to the presence of intestinal metaplasia.31
This description of the histogenesis agrees with our find-
ings, since by the BPA classification, the ABE pattern
showed a direct relationship with the adjacent columnar
type, independent of the presence of intestinal metaplasia.
Laurén’s classification identified more intestinal adeno-
carcinomas (61%) than the BPA classification (23%). This
occurred because there was a migration factor, with tumors
classified as gastric pattern in the BPA classification (tubu-
lar or tubulo-papilliferous with foveolar structure and mi-
crotubular adenocarcinomas) migrating to intestinal types
in Laurén’s classification. In the latter, the histogenesis of
tumors is not taken into consideration, but rather only their
morphological aspects. The BPA classification, modified
from Nakamura, considers both the histogenetic and the
morphological aspects. Thus, adenocarcinomas are consid-
ered to develop from gastric glandular epithelia and present
tubular structure and foveolar or microtubular morphology.
Most pathologists classify ABE according to morpho-
logical classifications; therefore, the microtubular and fo-
veolar structure adenocarcinomas are more frequently clas-
sified as intestinal adenocarcinomas, and this explains their
high incidence rates in the international literature.9,10,23,26
However, undifferentiated or gastric (signet ring cells and
mucocellular) adenocarcinomas have been described by
some authors, with lower incidence.9,21,23 These tumors can
originate from gastric metaplasia that is also present in the
specialized epithelium of Barrett´s esophagus.
The cell proliferation index, as revealed by IHC tests
for Ki67 and possible genetic mutations (p53 gene and oth-
ers), have been extensively reported in the literature, with
the aim of identifying the evolution of Barrett´s esophagus
to adenocarcinoma.41,43,44 The relationship of the adenocar-
cinoma with its adjacent columnar epithelium had not been
studied.
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We observed extensive expression of Ki67 in our mate-
rial, showing a high cell proliferation index, both in the
tumors and in the columnar epithelia. Other authors have
reported lower expression of Ki67 (14%) in patients with
Barrett´s esophagus without adenocarcinoma, and higher
(87%) in patients with ABE.44 Halm et al. found higher ex-
pression of Ki67 in Barrett´s esophagus with intestinal meta-
plasia compared with Barrett´s esophagus with gastric meta-
plasia, and rates were even higher in ABE.41 We did not ob-
serve any differences between Ki67 expression in different
columnar epithelial metaplasias. Probably, the extensive
Ki67 expression in both tumors and columnar epithelium
could be explained by the fact that both tissue types were
removed from patients who had already developed ABE.
We found low p53 expression, just 33% in adjacent epi-
thelia, and 58% in adenocarcinomas. This could be a sign
of normal protein accumulation in the cell nuclei, without
confirmed genetic mutation. Other authors describe p53 ex-
pression ranging from 60.9% to 65% in invading carcino-
mas.46,48 The p53 gene function may be inactivated by other
mechanisms without a direct relationship to genetic muta-
tion. On the other hand, some mutations observed in mo-
lecular biology do not yield positive expression of p53 in
IHC studies.27,49,50
Expression of p53 in adenocarcinoma and adjacent co-
lumnar epithelium was not correlated in our study. Three
patients with positive tumor expression of p53 did not ex-
press this in the adjacent epithelium, and we did not ob-
serve any quantitative evolution in p53 expression when
adjacent columnar epithelium and adenocarcinoma were
compared.
Molecular events such as mutations, allelic loss, ge-
nomic instability, and genetic methylations do not occur
systematically, which makes a standard molecular develop-
ment of ABE difficult to find.
The p53 expression in one patient in our study (# 12)
suggests that the epithelial origin of the tumor was in a gas-
tric cell without intestinal metaplasia; however, it is only
one case, and further studies should be conducted to corre-
late the histogenesis of the tumors and genetic markers.
CONCLUSION
Currently, anatomopathological aspects are still the best
biological indicators for Barrett´s esophagus follow-up with
the purpose of obtaining early diagnosis of ABE. The most
important area to search for precocious adenocarcinoma
during endoscopic examination is the transitional region
between squamous and columnar epithelium. Segments of
Barrett´s esophagus longer than 3 cm should be a red flag
for increased risk for development of adenocarcinoma and
indicate the need for close follow-up.
Adenocarcinoma does not always develop over intesti-
nal metaplasia epithelium (2 patients, 15.4%, did not
present with intestinal metaplasia). The presence of intesti-
nal metaplasia does not mean that this epithelium will
originate a tumor. According to Nakamura, an adenocarci-
noma can develop from gastric cells (foveolars). Barrett’s
esophagus is a columnar epithelium that can be modified,
just as the gastric mucosa can, and it can originate any type
of adenocarcinoma.
We conclude that follow-up in cases of long Barrett´s
esophagus segments (more than 3 cm) is important and
should be performed in all patients, independent of the type
of columnar epithelium, with or without intestinal metapla-
sia, as revealed by endoscopic biopsy.
RESUMO
SZACHNOWICZ S e col. Origem do adenocarcinoma no
esôfago de Barrett: bases histopathológicas e expressão
dos genes p53 e Ki67. CLINICS 60(2):103-112, 2004.
O esôfago de Barrett é definido como a substituição do
epitélio escamoso do esôfago distal por epitélio colunar. A
metaplasia intestinal no esôfago de Barrett é considerada
por muitos como o principal fator de risco para o desenvol-
vimento do adenocarcinoma. Embora já descrito, o
adenocarcinoma do tipo difuso e o esôfago de Barrett sem
metaplasia intestinal, são raros e pouco estudados.
OBJETIVO E MÉTODO: O presente estudo objetivou
o cálculo da prevalência do adenocarcinoma no esôfago de
Barrett, assim como a análise macroscópica e microscópica
detalhada de treze pacientes operados no período de 1990
a 2002, com realização de estudo imunohistoquímico do
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p53 e Ki67, correlacionando o tipo de tumor com o epitélio
adjacente a este.
RESULTADOS: Obtivemos uma prevalência de 5,7%
de adenocarcinoma em pacientes internados para tratamento
cirúrgico de esôfago de Barrett . Encontraram-se tumores
relativamente grandes, com média de 4,67 ± 2,28 cm, e sem-
pre em esôfago de Barrett longo, com média de 7,71 ± 1,5
cm. Observou-se tendência de os tumores se localizarem
próximos à transição escamo-colunar. O estudo histológico
mostrou dois pacientes (15,4%) que apresentavam esôfago
de Barrett adjacente ao tumor do tipo juncional sem pre-
sença de metaplasia intestinal. Classificaram-se os tumores
segundo a classificação japonesa de Nakamura (23% de pa-
drão diferenciado ou intestinal e 77% de padrão
indiferenciado ou gástico) e pela classificação de Laurén
(61% intestinais e 39% difusos). A diferença decorre da mi-
gração dos tumores microtubulares e foveolares do padrão
gástrico para o tipo intestinal de Laurén. O estudo do Ki67
foi fortemente positivo em todos os pacientes, mostrando
o alto índice de proliferação celular no epitélio colunar e
no tumor. O p53 mostrou-se negativo em 66,7% dos paci-
entes no epitélio colunar e 41,7% no tumor, não mostran-
do correlação entre os dois materiais.
CONCLUSÃO: O adenocarcinoma se desenvolve sobre
o esôfago de Barrett a partir do epitélio colunar misto, in-
testinal, bem como do juncional, apresentando padrão tan-
to gástrico como intestinal; portanto tumores podem se de-
senvolver em epitélio colunar sem metaplasia intestinal o
qual também deve ser seguido, principalmente quando for
extenso.
UNITERMOS: Esôfago de Barrett. Refluxo
Gastroesofágico. Neoplasia de Esôfago. Adenocarci-
noma. Imunohistoquímica.
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